View of Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

Return to Article Details Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations Download Download PDF